TGA approval of Skyrizi

For Community

For Fellows and Trainees

For Health Professionals

Posted 1 year ago

The Therapeutic Goods Adminisation (TGA) has granted regulartory approval for Skyrizi (Risankizumab) for the treatment of moderate to severe plaque psoriasis in adults who are candidates for phototherapy or systemic therapy.

It is an IL-23 blocking biological agent. Note that Skyrizi is not listed on the Pharmaceutical Benefits Scheme (PBS).

Visit the Abbvie website for more information or the GuildLink website for product information.